Comparing Cognitive-Targeted and Fusion-Targeted Prostate Biopsies to Detect Prostate Cancer

What this Trial Is About

Researchers are comparing two prostate biopsy techniques to detect prostate cancer cognitive-targeted biopsy CTB and magnetic resonance imaging-ultrasound fusion-targeted biopsy FTB. The study focuses on biopsy-nafve men suspected of having prostate cancer based on abnormal digital rectal exams and specific prostate-specific antigen PSA levels. It aims to evaluate how accurately each method detects cancer, the pathological results from each biopsy, and how the surgeons performance may affect the procedure. Participants will have a multiparametric MRI of the prostate, and only those with specific suspicious lesions PI-RADS 4 or 5 will join the trial. Each participant undergoes both biopsy methods during the same session under local or regional anesthesia, using a BK3000 ultrasound system. Two surgeons will perform the procedures, and participants are randomly assigned to one of them. This design allows a direct comparison of the two biopsy techniques within the same patient. Throughout the study, researchers will monitor various factors including cancer detection rates based on tissue analysis, clinically significant cancer rates, biopsy procedure time, lesion size on MRI, and procedural details by surgeon. These outcomes will be assessed during the biopsy session. The study is conducted at Menoufia University, with results to be reported after study completion. Participation involves a single biopsy session with detailed imaging and biopsy procedures under professional care.

Cognitive and Fusion Prostatic Biopsy